FINWIRES · TerminalLIVE
FINWIRES

Kiniksa's Arcalyst Growth Outlook Strengthens, Wedbush Says

By

Kiniksa Pharmaceuticals International (KNSA) is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes, Wedbush Securities said Tuesday in a report.

Arcalyst's growth continues to be driven by broadening prescriber adoption, with more than 5,000 clinicians having used the therapy since launch and returning users accounting for over half of new scripts, Wedbush said.

Kiniksa shares face additional upside as Arcalyst's cash generation supports development of the company's pipeline and as newer recurrent pericarditis assets create a path for long-term expansion, the report said.

Wedbush highlighted KPL-387, Kiniksa's next-generation treatment candidate, as a "de-risked" opportunity that may strengthen the company's position in IL-1 blockade for recurrent pericarditis while improving the franchise's long-term economics

Wedbush increased its price target on Kiniksa's stock to $99 from $72 and maintained its outperform rating.

Price: $79.38, Change: $+15.84, Percent Change: +24.93%

Related Articles

Wire

AuMEGA Metals Starts Inaugural Diamond Drilling at Canada Targets; Shares Fall 9%

AuMEGA Metals (ASX:AAM) started inaugural diamond drilling at targets at Isle aux Morts Granite and and the adjoining Cape Ray West area along the Cape Ray shear zone in Canada, according to a Tuesday Australian bourse filing.The drilling program is designed to test a series of structural, geochemical, and geophysical targets defined by integrating geological mapping, surface geochemistry, geophysics, and structural interpretation, per the filing.The company's shares fell nearly 9% in recent trading on Tuesday.

ASX:AAM
Wire

Brown & Brown Q2 Adjusted Earnings, Revenue Rise

Brown & Brown (BRO) reported Q2 adjusted earnings late Monday of $1.07 per diluted share, up from $1.03 a year earlier.Analysts polled by FactSet expected $1.08.Revenue in the three months ended June 30 rose to $1.68 billion from $1.29 billion a year earlier.Analysts expected $1.71 billion.The company's shares fell 1.8% in after-hours trading.

$BRO
Wire

Celestica Q2 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Celestica (CLS) reported Q2 adjusted earnings late Monday of $2.54 per diluted share, up from $1.39 a year earlier.Analysts polled by FactSet expected $2.27.Revenue in the three months ended June 30 rose to $4.7 billion from $2.89 billion a year earlier.Analysts expected $4.33 billion.Celestica expects Q3 adjusted EPS of $2.88 to $3.08 on revenue of $5.25 to $5.55 billion.Analysts project EPS of $2.65 on revenue of $4.94 billion.The company boosted full-year guidance to adjusted EPS of $11.30 on revenue of $20.5 billion from the prior forecast of EPS of $10.15 on revenue of $19 billion.Analysts project EPS of $10.13 on revenue of $18.95 billion.Celestica shares rose 9.4% in after-hours trading.

$CLS